Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

Core Viewpoint - Adial Pharmaceuticals has received a new patent that enhances its genetic-based approach to treating alcohol and opioid-related disorders, allowing for personalized treatment plans based on patients' genetic profiles [1][2][3] Company Overview - Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for addiction and related disorders, with its lead investigational drug AD04 targeting Alcohol Use Disorder (AUD) [4] - The company recently conducted the ONWARD™ pivotal Phase 3 clinical trial for AD04, which showed promising results in reducing heavy drinking among patients with specific genetic markers [4] Patent Details - The newly issued patent (number 12,226,401) covers methods for identifying genetic markers in patients with alcohol or opioid-related disorders, specifically targeting genotypes such as the AC genotype of rs17614942 in the HTR3B gene and the AG genotype of rs1150226 in the HTR3A gene [2] - This patent allows healthcare providers to create tailored treatment plans using AD04, aligning therapeutic approaches with genetic data to improve treatment outcomes [2][3] Strategic Implications - The patented approach is expected to transform the treatment of alcohol and opioid dependence by utilizing genetic information to guide therapy, potentially offering new options for millions suffering from addiction [3][4] - AD04 is also believed to have applications in treating other addictive disorders, including Opioid Use Disorder, gambling, and obesity [4]